8-K: MindMed to Voluntarily Delist from Cboe Canada, Focuses Trading on Nasdaq

MindMed will delist its common shares from Cboe Canada on April 10, 2024, to consolidate trading on Nasdaq.

Summary

• Mind Medicine (MindMed) Inc. has announced it will voluntarily delist its common shares from the Cboe Canada exchange.
• The delisting is effective at the close of markets on April 10, 2024.
• The company's shares will continue to trade on the Nasdaq Global Select Market under the symbol MNMD.
• MindMed believes the trading volume on Cboe Canada does not justify the costs and administrative burden of maintaining the dual listing.
• Approximately 95% of MindMed's trading volume occurs on Nasdaq.
• The company expects to redirect the savings from the delisting to initiatives that will generate shareholder value.
• Canadian shareholders can continue to trade their shares on Nasdaq through their brokers.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the delisting is presented as a strategic move to reduce costs and improve efficiency, with no negative impact on shareholders' ability to trade the stock.

Positives

• The delisting will result in cost savings for the company.
• The company will be able to redirect resources to initiatives that generate shareholder value.
• Shareholders will still have access to trade the company's shares on Nasdaq.
• The company will continue to be a reporting issuer in Canada.

Negatives

• The delisting means that the company will no longer have a dual listing on Cboe Canada.

Risks

• There are risks and uncertainties that could cause actual results to differ materially from the forward-looking statements.
• These risks include the satisfaction of customary closing conditions for the underwritten offering and the concurrent private placement.

Future Outlook

The company anticipates that the delisting will allow them to redirect resources to initiatives that will generate shareholder value and that shareholders will continue to have access to trade the company's shares on Nasdaq.

Management Comments

• The company believes that the trading volume of its common shares on Cboe Canada no longer justifies the expense and administrative requirements associated with maintaining this dual listing.
• The substantial savings in exchange fees, legal fees, and managerial time and effort to maintain a dual listing can be redirected to initiatives intended to generate shareholder value.

Industry Context

This move reflects a trend of companies streamlining their listings to focus on primary exchanges with higher trading volumes and lower costs. It is not uncommon for companies to delist from secondary exchanges when the trading volume does not justify the expense.

Comparison to Industry Standards

• Many companies with dual listings on smaller exchanges often choose to delist from those exchanges to reduce costs and focus on their primary listing.
• This is a common practice for companies that find the trading volume on a secondary exchange is not significant enough to justify the expense and administrative burden.
• For example, several smaller Canadian companies that also list on the NYSE or Nasdaq have delisted from the TSX Venture Exchange or similar exchanges for similar reasons.

Stakeholder Impact

• Shareholders will continue to be able to trade the company's shares on Nasdaq.
• The company expects to redirect resources to initiatives that will generate shareholder value.

Next Steps

• The company will complete the delisting process from Cboe Canada on April 10, 2024.
• The company will continue to trade on Nasdaq under the symbol MNMD.
• The company will redirect the savings from the delisting to initiatives that will generate shareholder value.

Key Dates

Keywords

delisting, Cboe Canada, Nasdaq, MNMD, trading volume, dual listing, cost savings, shareholder value, biopharmaceutical, brain health disorders